Viking Therapeutics(NASDAQ) VKTX

Viking Therapeutics makes new medicines for people with weight and hormone-related health issues. These treatments help patients manage conditions like obesity and liver disease through pills or injections. The company focuses on testing these drugs in clinical trials to ensure they are safe.

A Full Medicine Cabinet

• VK2735: Dual hormone receptor agonist designed to treat obesity; available in both injectable and oral tablet forms.
• VK2809: Oral drug that targets the thyroid hormone receptor beta to reduce fat in the liver.
• VK0214: Medicine being tested for a rare genetic brain disorder called X-linked adrenoleukodystrophy.
• VK3019: Early-stage compound targeting amylin, a hormone that helps regulate appetite and blood sugar.
• VK5211: Oral treatment designed to help patients regain muscle mass after hip fracture surgery.

Partnerships and Progress

• In March 2025, Viking signed manufacturing agreements with Corden Pharma Colorado, Inc. to produce its weight-loss drug.
• The company started two Phase 3 clinical studies for its subcutaneous obesity treatment in June 2025.
• Viking formed an Irish subsidiary called Viking Therapeutics Ireland Limited in January 2025.
• Management is defending its rights against Ligand Pharmaceuticals Incorporated following a 2026 dispute over drug licenses.

Why This Biotech Stands Out

Viking uses its expertise in hormone receptors to develop drugs that target specific tissues like the liver and muscle. The company operates with a small team of 45 employees while advancing several late-stage clinical programs simultaneously.

By the Numbers in 2026

• Operating loss reached $164.1 million in Q1 2026, deepening from $55.5 million in Q1 2025.
• Net loss was $158.3 million for the quarter ended March 31, 2026, worsening from $45.6 million year-over-year.
• Research and development spending reached $150.2 million in Q1 2026, up from $41.4 million in Q1 2025.
• Cash and short-term investments totaled $603 million as of March 31, 2026.
• Operating cash flow was negative $114 million in Q1 2026, worsening from negative $52.3 million in Q1 2025.

Bottom Line

Viking has transitioned from early research into late-stage testing of its primary weight-loss and liver disease drugs. While the company reports no revenue, it continues to invest heavily in its manufacturing capacity and global clinical trials.